AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26264470 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk test (6MWT)
Number of subjects: 20
Study 26264470 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-shuttle walk test (ESWT)
Number of subjects: 20
Study 26264470 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 20
Study 23565709 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI-1678
Number of subjects: 0
Study 23565709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0
Study 23565709 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 21869635 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel-raise training (100 heel raises per day for 2 months)
Number of subjects: 26
Study 19951210 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention (30 minutes per day, 5 days per week)
Number of subjects: 137
Study 19951210 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance exercises (11 exercises, twice per week)
Number of subjects: 137
Study 19951210 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis for walking adherence
Number of subjects: 137
Study 19951210 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis for balance exercises adherence
Number of subjects: 137
Study 17573988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 7287
Study 15164437 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 455
Study 15164437 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus tamoxifen
Number of subjects: 455
Study 11563898 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 72
Study 11563898 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ANH)
Number of subjects: 72
Study 9451748 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 with chemotherapy (5-fluorouracil and leucovorin)
Number of subjects: 17
Study 9451748 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 17
Study 15374271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (IP) 3 x 200 mg/day
Number of subjects: 84
Study 15374271 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 84
Study 2828820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg/d for 5 days)
Number of subjects: 18
Study 2828820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31676895 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery within 49 days
Number of subjects: 643
Study 31676895 — intervention group
Group type: COMPARATOR
Intervention: Surgery after 50 days or longer
Number of subjects: 643
Study 31676895 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete histological response (ypT0)
Number of subjects: 643
Study 31676895 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lymph node metastases (ypT0N1)
Number of subjects: 643
Study 27491303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine kinesiotherapy and posture correction exercises plus Autogenic Training (AT)
Number of subjects: 152
Study 27491303 — intervention group
Group type: COMPARATOR
Intervention: Autogenic Training (AT) only
Number of subjects: 152
Study 28984527 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal human milk odor
Number of subjects: 0
Study 28984527 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25646357 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF)
Number of subjects: 240
Study 25646357 — intervention group
Group type: COMPARATOR
Intervention: cisplatin plus fluorouracil (CF)
Number of subjects: 240
Study 24244295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Bayesian Network (DBN) analysis of inflammatory mediators
Number of subjects: 49
Study 20378921 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release methylphenidate (MPH‐IR)
Number of subjects: 54
Study 20378921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 18186564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alpha-2a (135 microg weekly for 48 weeks)
Number of subjects: 36
Study 18186564 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36
Study 17213004 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (S‐amlodipine 5 mg p.o.)
Number of subjects: 18
Study 17213004 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (racemate 10 mg p.o.)
Number of subjects: 18
Study 17213004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study 14498767 — intervention group
Group type: EXPERIMENTAL
Intervention: CPH 82 (Reumacon)
Number of subjects: 0
Study 10958764 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta32CCR5 heterozygous patients (d/w)
Number of subjects: 107
Study 10958764 — intervention group
Group type: COMPARATOR
Intervention: CCR5 wild-type patients (w/w)
Number of subjects: 107
Study 8643897 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy (BEAM) with autologous stem cell rescue
Number of subjects: 0
Study 8643897 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 0
Study 8643897 — intervention group
Group type: COMPARATOR
Intervention: CHOEP
Number of subjects: 0
Study 1448312 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 6 months
Number of subjects: 111
Study 1448312 — intervention group
Group type: COMPARATOR
Intervention: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months
Number of subjects: 111
Study 1448312 — intervention group
Group type: COMPARATOR
Intervention: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months (specific subgroup)
Number of subjects: 111
Study 3882143 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 0
Study 3882143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3882143 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg, three times daily
Number of subjects: 0
Study 3882143 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg (single dose)
Number of subjects: 0
Study 3882143 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide and sulpiride
Number of subjects: 0
Study 31593541 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 eHealth intervention
Number of subjects: 72
Study 31593541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 27362792 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive control training (CCT)
Number of subjects: 34
Study 27362792 — intervention group
Group type: COMPARATOR
Intervention: Low cognitive load training (active control condition)
Number of subjects: 34
Study 26649535 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing via the Internet
Number of subjects: 0
Study 26649535 — intervention group
Group type: COMPARATOR
Intervention: Active control (reading a book on history of hearing aids)
Number of subjects: 0
Study 23635681 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 292
Study 21262402 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD, 20μg/day)
Number of subjects: 49
Study 21262402 — intervention group
Group type: COMPARATOR
Intervention: Strontium ranelate (SrR, 2g/day)
Number of subjects: 49
Study 19136303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate 15 mg weekly for 40 weeks (7.5 mg weekly for 4 weeks, then 10 mg weekly for 4 weeks, then 15 mg weekly for 32 weeks)
Number of subjects: 60
Study 19136303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17105674 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 17105674 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 0
Study 15053702 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice condition (8 days of practice passing through apertures)
Number of subjects: 0
Study 15053702 — intervention group
Group type: COMPARATOR
Intervention: Initial estimation without practice
Number of subjects: 0
Study 11684979 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (CPB) at 35.5‐36.5 degrees C
Number of subjects: 300
Study 11684979 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (CPB) at 28‐30 degrees C
Number of subjects: 300
Study 9741509 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 318
Study 9741509 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 40 mg/day + colestipol 20 g/day
Number of subjects: 318
Study 9741509 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 80 mg/day
Number of subjects: 318
Study 9741509 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 318
Study 9741509 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 318
Study 9741509 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 318
Study 8000839 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol-300 (300 mg I ml-1)
Number of subjects: 198
Study 8000839 — intervention group
Group type: COMPARATOR
Intervention: iopromide-300 (300 mg I ml-1)
Number of subjects: 198
Study 3404813 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 7
Study 3404813 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichlormethiazide
Number of subjects: 7
Study 31708380 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg/day
Number of subjects: 703
Study 31708380 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg/day
Number of subjects: 703
Study 31708380 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 0.5-2 mg/day
Number of subjects: 703
Study 31708380 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg/day (post hoc analysis)
Number of subjects: 703
Study 31712330 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy
Number of subjects: 540
Study 31712330 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 540
Study 31712330 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 540
Study 28570317 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus nebulized epinephrine (n = 8)
Number of subjects: 16
Study 28570317 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (n = 8)
Number of subjects: 16
Study 25928457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with etoposide and cisplatin (BEEP) every 3 weeks for a maximum of 6 cycles
Number of subjects: 8
Study 25928457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with etoposide and cisplatin (BEEP)
Number of subjects: 8
Study 23849306 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma FGF‐23 concentration (highest tertile)
Number of subjects: 110
Study 23849306 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous variable of FGF‐23
Number of subjects: 110
Study 20418538 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg) before surgical incision
Number of subjects: 29
Study 20418538 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil infusion (0.25 μg/kg/h after a load of 0.75 μg/kg)
Number of subjects: 29
Study 18665000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT for children
Number of subjects: 61
Study 18665000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT for children plus parent training
Number of subjects: 61
Study 18665000 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 61
Study 16480794 — intervention group
Group type: EXPERIMENTAL
Intervention: TdPa formulations with inactivated poliomyelitis vaccine (IPV)
Number of subjects: 0
Study 16480794 — intervention group
Group type: EXPERIMENTAL
Intervention: TdPa formulations without inactivated poliomyelitis vaccine (IPV)
Number of subjects: 0
Study 16480794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse booster model with whole cell pertussis vaccine priming
Number of subjects: 0
Study 16480794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse model
Number of subjects: 0
Study 12562658 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg p.o. on day 1, followed by dexamethasone 4 mg p.o. od for 5 days
Number of subjects: 258
Study 12562658 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 20 mg p.o. tds combined with dexamethasone 4 mg p.o. od for 5 days
Number of subjects: 258
Study 12562658 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron in the delayed phase
Number of subjects: 258
Study 12562658 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide in the delayed phase
Number of subjects: 258
Study 11078032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 417
Study 11078032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 9302466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy at 2 atmospheres absolute pressure
Number of subjects: 32
Study 9302466 — intervention group
Group type: COMPARATOR
Intervention: Air treatment at 1.1 atmosphere absolute pressure
Number of subjects: 32
Study 8349379 — intervention group
Group type: EXPERIMENTAL
Intervention: lorcainide
Number of subjects: 95
Study 8349379 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study 3098270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (0.5 mg intravenous bolus)
Number of subjects: 6
Study 3098270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3098270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 and ethanol
Number of subjects: 6
Study 31268629 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 998
Study 29883979 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable stent placement
Number of subjects: 66
Study 29883979 — intervention group
Group type: COMPARATOR
Intervention: Dilation
Number of subjects: 66
Study 29883979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 26481332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (re-esterified triacylglycerol fish oil capsule)
Number of subjects: 314
Study 26481332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish (lightly grilled oily fish)
Number of subjects: 314
Study 26481332 — intervention group
Group type: COMPARATOR
Intervention: Control (no fish)
Number of subjects: 314
Study 25304298 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Number of subjects: 130
Study 25304298 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Number of subjects: 130
Study 25304298 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radical hypofractionated radiotherapy
Number of subjects: 130
Study 22373759 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate level of transference intervention
Number of subjects: 100
Study 22373759 — intervention group
Group type: COMPARATOR
Intervention: No transference intervention
Number of subjects: 100
Study 20351373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (20 min session at GB1, GB14, and BL1)
Number of subjects: 48
Study 20351373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture (20 min session with needles inserted in false points)
Number of subjects: 48
Study 20351373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 18375882 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Care (GC)
Number of subjects: 904
Study 18375882 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 904
Study 15822419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60% end‐tidal concentration
Number of subjects: 25
Study 15822419 — intervention group
Group type: COMPARATOR
Intervention: Control group (0% nitrous oxide)
Number of subjects: 25
Study 12912859 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a (22 micro g three times a week subcutaneously, increased to 44 micro g and then to 88 micro g if no response, maximum duration of treatment 8 weeks)
Number of subjects: 18
Study 12912859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12912859 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a
Number of subjects: 18
Study 10333383 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD patients
Number of subjects: 14
Study 10333383 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study 7795873 — intervention group
Group type: EXPERIMENTAL
Intervention: ROHO dry‐floatation mattress
Number of subjects: 12
Study 7795873 — intervention group
Group type: COMPARATOR
Intervention: Clinitron bed
Number of subjects: 12
Study 1971649 — intervention group
Group type: EXPERIMENTAL
Intervention: tobramycin
Number of subjects: 77
Study 1971649 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 77
Study 7000128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 2 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Number of subjects: 12
Study 7000128 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 10 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Number of subjects: 12
Study 30426323 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 99
Study 28063909 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound surgery
Number of subjects: 57
Study 28063909 — intervention group
Group type: COMPARATOR
Intervention: Uterine artery embolization
Number of subjects: 57
Study 25787200 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam 25 mg
Number of subjects: 192
Study 25787200 — intervention group
Group type: EXPERIMENTAL
Intervention: fasiglifam 50 mg
Number of subjects: 192
Study 25787200 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 192
Study 24065443 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg LD alone
Number of subjects: 282
Study 24065443 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg plus prasugrel 60 mg
Number of subjects: 282
Study 24065443 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg plus prasugrel 30 mg
Number of subjects: 282
Study 21220618 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doxorubicin and daily oral cyclophosphamide with granulocyte colony-stimulating factor support for 15 weeks (continuous arm)
Number of subjects: 372
Study 21220618 — intervention group
Group type: COMPARATOR
Intervention: Standard doxorubicin and cyclophosphamide administered for five cycles (standard arm)
Number of subjects: 372
Study 21220618 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel for 12 weeks before surgery (both arms)
Number of subjects: 372
Study 21220618 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 372
Study 19766789 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection (wedge resections for 44 patients and segmentectomy for 2 patients)
Number of subjects: 46
Study 19766789 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection
Number of subjects: 46
Study 18002724 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LI 4 (Hegu) and LI 11 (Quchi)
Number of subjects: 10
Study 15333270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening for seven years
Number of subjects: 77080
Study 15333270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic examinations
Number of subjects: 77080
Study 15466792 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraCoil stent
Number of subjects: 266
Study 15466792 — intervention group
Group type: COMPARATOR
Intervention: PTA (balloon angioplasty)
Number of subjects: 266
Study 9895079 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with ropivacaine 0.2% plus sufentanil (Group 1)
Number of subjects: 86
Study 9895079 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine 0.175% plus sufentanil (Group 2)
Number of subjects: 86
Study 7736883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 192
Study 7736883 — intervention group
Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 192
Study 2076717 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine (A)
Number of subjects: 417
Study 2076717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole (N)
Number of subjects: 417
Study 2076717 — intervention group
Group type: EXPERIMENTAL
Intervention: Etophamide (E)
Number of subjects: 417
Study 2076717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole and Aminosidine (NA)
Number of subjects: 417
Study 2076717 — intervention group
Group type: EXPERIMENTAL
Intervention: Etophamide and Nimorazole (EA)
Number of subjects: 417
Study 2076717 — intervention group
Group type: EXPERIMENTAL
Intervention: Etophamide and Aminosidine (EA)
Number of subjects: 417
Study 6987483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 40
Study 6987483 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 40
Study 31732233 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly blood sampling
Number of subjects: 7454
Study 31732233 — intervention group
Group type: COMPARATOR
Intervention: Blood sampling every 6 weeks
Number of subjects: 7454